International BioFest 2016 is coming to Melbourne
12 October, 2016From 24–27 October 2016, Melbourne Convention Centre will play host to International BioFest — a series of three major life sciences conferences taking place at the one time.
New venture capital fund for Australian healthcare start-ups
11 October, 2016BioScience Managers has announced the launch of a new venture capital fund for Australia's innovative healthcare and biomedical research sectors.
A potent antioxidant from apples and water
10 October, 2016A scientist from the University of Newcastle has developed what is claimed to be the most potent dietary antioxidant available anywhere in the world.
Peanut allergy treatment gets a $15 million boost
06 October, 2016OneVentures will lead a $15 million funding round for a promising new treatment for peanut allergy in children, developed at the Murdoch Childrens Research Institute.
Titratable sleep apnoea device cleared by FDA
28 September, 2016Oventus Medical has received clearance from the US FDA for the O2Vent T device, an oral appliance intended to alleviate snoring and obstructive sleep apnoea.
Australian CF drug approved in Russia
28 September, 2016Cystic fibrosis drug Bronchitol, from Pharmaxis, has been approved for marketing in Russia for the treatment of both paediatric and adult CF patients.
Just add water: on-demand pharmaceutical manufacturing
26 September, 2016US researchers have been working on a molecular manufacturing method that can produce a broad range of biomolecules anywhere in the world, without power or refrigeration.
Most innovative biotech company announced
23 September, 2016Swiss biotech company BioLingus has been selected as the 2016 winner of The CEO Magazine's Most Innovative Biotech Company award.
Duchenne muscular dystrophy drug approved by FDA
22 September, 2016The US FDA has announced the approval of a Western Australian-developed drug to treat Duchenne muscular dystrophy (DMD) — a rare and fatal muscle wasting disease affecting one in 3500 boys worldwide.
Making drug development less secretive could lead to quicker, cheaper therapies
15 September, 2016 by Matthew Todd, University of Sydney and Alice Williamson, University of SydneyWith the right investment, an open source drug discovery system — based on sharing all information in the public domain in real time — might compete with the traditional pharmaceutical industry to deliver the drugs we need.
Sartorius Stedim Biotech Connect Upstream bioprocessing platform
11 September, 2016Sartorius Stedim Biotech (SSB) has developed an innovative and fully integrated technology platform to meet the requirements of today's upstream bioprocessing.
PPS to treat viral joint pain and arthritis
08 September, 2016Paradigm Biopharmaceuticals and Griffith University have announced pentosan polysulfate sodium (PPS) as a potential breakthrough in the treatment for alphavirus-induced arthralgia and arthritis.
Point-of-care testing for infectious diseases set to rise
05 September, 2016The infectious diseases point-of-care testing (POCT) market is set to rise from $696.1 million in 2015 to just over $1.17 billion by 2022, representing a compound annual growth rate of 7.7%.
R&D Tax Incentive cuts proposed
05 September, 2016AusBiotech is not happy with some of the savings measures included in the Omnibus Savings Bill — specifically, the proposed cuts to the Research & Development (R&D) Tax Incentive.
Better method of bone regeneration
30 August, 2016Biomedical engineers have used a cheap, commercially produced polymer to assist in bone regeneration, which could result in better therapies for spinal injuries, bone grafts and other orthopaedic surgeries.
